Corporate Governance
UCB Governance
| Title | Format | Download |
|---|---|---|
|
Articles of Association (ENG)
|
PDF
|
|
|
Articles of Association (FR)
|
PDF
|
|
|
Articles of Association (NL)
|
PDF
|
| Title | Format | Download |
|---|---|---|
|
Special report of the Board - 27 February 2024 (ENG)
|
PDF
|
|
|
Special report of the Board - 27 February 2024 (FR)
|
PDF
|
|
|
Special report of the Board - 27 February 2024 (NL)
|
PDF
|
Remuneration Policy 2025
| Title | Format | Download |
|---|---|---|
|
Remuneration Policy 2025 (ENG)
|
PDF
|
|
|
Remuneration Policy 2025 (FR)
|
PDF
|
|
|
Remuneration Policy 2025 (NL)
|
PDF
|
Related Press Releases
Corporate Governance Charter
UCB Dealing Code
Code of Conduct
Board of Directors
To enhance the overall effectiveness of the Board by ensuring focus, oversight and monitoring of sensitive areas, the Board has created three specialist committees.
Composition
-
the Audit Committee
The Audit Committee assists the Board in its responsibility of monitoring the management of UCB and the UCB Group as a whole.
3 members (67% independent):
- Rodolfo J. Savitzky (Chair & Independent Director)
- Maëlys Castella (Independent Director)
- Cédric van Rijckevorsel (Director)
-
the Governance, Nomination and Compensation Committee (GNCC)
The Governance, Remuneration and Nomination Committee (GNCC) ensures that the appointment and re-election process is organized objectively and professionally and proposes the remuneration policy for non-executive Directors and executive managers.
5 members (80% independent):
- Kay Davies (Chair & Independent Director)
- Charles-Antoine Janssen (Director)
- Pierre Gurdjian (Independent Director)
- Nefertiti Greene (Independent Director)
- Ulf Wiinberg (Independent Director)
-
the Scientific Committee
The Scientific Committee assists the Board when reviewing the quality of UCB’s R&D science and its competitive standing. It assesses the strategy proposed by UCB’s management in R&D matters and communicates its recommendations to the Board.
2 members (100% independent):
- Kay Davies (Independent Director)
- Dolca Thomas (Independent Director)
Jonathan Peacock
Independent Director
Chair of the Board
First appointed in 2021
End of term in 2025
Charles-Antoine Janssen
Director
Vice-chair of the Board
Member of the GNCC
First appointed in 2012
End of term in 2028
Jean-Christophe Tellier
Executive Director
First appointed in 2014
End of term in 2026
Maëlys Castella
Independent Director
Member of the Audit Committee
First appointed in 2023
End of term in 2027
Kay Davies
Independent Director
Member of the Scientific Committee
Chair of the GNCC
First appointed in 2014
End of term in 2026
Pierre Gurdjian
Independent Director
Member of the GNCC
First appointed in 2016
End of term in 2028
Cédric van Rijckevorsel
Director
Member of the Audit Committee
First appointed in 2014
End of term in 2026
Ulf Wiinberg
Independent Director
Member of the GNCC
First appointed in 2016
End of term in 2028
Nefertiti Greene
Independent Director
Member of the GNCC
First appointed in 2024
End of term in 2028
Rodolfo Savitzky
Independent Director
Chair of the Audit Committee
First appointed in 2024
End of term in 2028
Dolca Thomas
Independent Director
Member of the Scientific Committee
First appointed in 2024
End of term in 2028
-
Honorary directors
- Karel Boone, Honorary Chair
- Evelyn du Monceau, Honorary Chair
- Mark Eyskens, Honorary Chair
- Georges Jacobs de Hagen, Honorary Chair
- Daniel Janssen, Honorary Deputy Chair
- Gerhard Mayr, Honorary Chair
- Prince Lorenz of Belgium
- Alan Blinken
- Alice Dautry
- Arnoud de Pret
- Roch Doliveux
- Peter Fellner
- Guy Keutgen
- Jean-Pierre Kinet
- Tom McKillop
- Gaëtan van de Werve
- Jean-Louis Vanherweghem
- Bridget van Rijckevorsel
- Norman J. Ornstein
- Bert de Graeve
-
Honorary chairmen of the Executive Committee
- Roch Doliveux
- Georges Jacobs de Hagen
- Daniel Janssen
Executive Committee
Jean-Christophe Tellier
Chief Executive Officer &
Chairman of the Executive Committee
Joined UCB in 2011
Appointed CEO in 2015
Emmanuel Caeymaex
Executive Vice President
Chief Commercial Officer
Joined UCB in 1994
Appointed in 2015
Sandrine Dufour
Executive Vice President
Chief Financial Officer
Joined UCB in July 2020
Appointed in July 2020
Jean Luc Fleurial
Executive Vice President
Chief Human Resources Officer
Joined UCB in 2017
Appointed in 2017
Fiona du Monceau
Executive Vice President
Patient Evidence
Joined UCB in 2024
Appointed in 2024
Kirsten Lund-Jurgensen
Executive Vice President
Patient Supply
Joined UCB in 2019
Appointed in 2019
Alistair Henry
Executive Vice President &
Chief Scientific Officer
Joined UCB in 2004
Appointed in 2024
Denelle J. Waynick Johnson
Executive Vice President &
General Counsel
Joined UCB in 2023
Appointed in 2023
Shareholders and Shareholder Meetings
Contact UCB IR Team
investor-relations@ucb.com or a specific team member:
Antje Witte, Head of Investor Relations
Tel: +32 2 559 9414
E-mail: Antje.Witte@ucb.com
Sahar Yazdian, Investor Relations Lead
Tel: +32 2 559 9137
E-mail: Sahar.Yazdian@ucb.com
UCB IR App
